Current perspectives on wearable rhythm recordings for clinical decision-making: the wEHRAbles 2 survey.


Journal

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology
ISSN: 1532-2092
Titre abrégé: Europace
Pays: England
ID NLM: 100883649

Informations de publication

Date de publication:
18 07 2021
Historique:
received: 25 02 2021
accepted: 02 03 2021
pubmed: 13 4 2021
medline: 10 8 2021
entrez: 12 4 2021
Statut: ppublish

Résumé

Novel wearable devices for heart rhythm analysis using either photoplethysmography (PPG) or electrocardiogram (ECG) are in daily clinical practice. This survey aimed to assess impact of these technologies on physicians' clinical decision-making and to define, how data from these devices should be presented and integrated into clinical practice. The online survey included 22 questions, focusing on the diagnosis of atrial fibrillation (AF) based on wearable rhythm device recordings, suitable indications for wearable rhythm devices, data presentation and processing, reimbursement, and future perspectives. A total of 539 respondents {median age 38 [interquartile range (IQR) 34-46] years, 29% female} from 51 countries world-wide completed the survey. Whilst most respondents would diagnose AF (83%), fewer would initiate oral anticoagulation therapy based on a single-lead ECG tracing. Significantly fewer still (27%) would make the diagnosis based on PPG-based tracing. Wearable ECG technology is acceptable for the majority of respondents for screening, diagnostics, monitoring, and follow-up of arrhythmia patients, while respondents were more reluctant to use PPG technology for these indications. Most respondents (74%) would advocate systematic screening for AF using wearable rhythm devices, starting at patients' median age of 60 (IQR 50-65) years. Thirty-six percent of respondents stated that there is no reimbursement for diagnostics involving wearable rhythm devices in their countries. Most respondents (56.4%) believe that costs of wearable rhythm devices should be shared between patients and insurances. Wearable single- or multiple-lead ECG technology is accepted for multiple indications in current clinical practice and triggers AF diagnosis and treatment. The unmet needs that call for action are reimbursement plans and integration of wearable rhythm device data into patient's files and hospital information systems.

Identifiants

pubmed: 33842972
pii: 6220446
doi: 10.1093/europace/euab064
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1106-1113

Informations de copyright

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2021. For permissions, please email: journals.permissions@oup.com.

Auteurs

Martin Manninger (M)

Division of Cardiology, Department of Medicine, Medical University of Graz, Graz, Austria.

David Zweiker (D)

Division of Cardiology, Department of Medicine, Medical University of Graz, Graz, Austria.
3rd Medical Department for Cardiology and Intensive Care, Klinik Ottakring, Vienna, Austria.

Emma Svennberg (E)

Department of Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden.

Sofia Chatzikyriakou (S)

Department of Cardiology, Clinic Saint-Jean, Brussels, Belgium.

Nikola Pavlovic (N)

University Hospital Center Sestre Milosrdnice, Zagreb, Croatia.

Junaid A B Zaman (JAB)

Royal Brompton Hospital, London, UK.
University of Southern California, Los Angeles, CA, USA.

Bratislav Kircanski (B)

Clinical Centre of Serbia, Pacemaker Centre, Belgrade, Serbia.

Radoslaw Lenarczyk (R)

Department of Cardiology, Congenital Heart Defects and Electrotherapy, Medical University of Silesia, Silesian Centre for Heart Disease, Zabrze, Poland.

Philippe Vanduynhoven (P)

Department of Cardiology, Arrhythmia Clinic, ASZ Aalst, Aalst, Belgium.

Jedrzej Kosiuk (J)

Helios Clinic Koethen, Koethen, Germany.

Tatjana Potpara (T)

Faculty of Medicine, University of Belgrade, Belgrade, Serbia.
Department for Intensive Care in Cardiac Arrhythmias, Cardiology Clinic, Clinical Centre of Serbia, Belgrade, Serbia.

David Duncker (D)

Hannover Heart Rhythm Center, Department of Cardiology and Angiology, Hannover Medical School, Carl-Neuberg-Str. 1, D-30625 Hannover, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH